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Abstract
Background: We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-
expressing oncolytic adenovirus, ONCOS-102, in patients with solid tumors refractory to available treatments. The
objectives of the study were to determine the optimal dose for further use and to assess the safety, tolerability and
adverse event (AE) profile of ONCOS-102. Further, the response rate and overall survival were evaluated as well as
preliminary evidence of disease control. As an exploratory endpoint, the effect of ONCOS 102 on biological
correlates was examined.
Methods: The study was conducted using a classic 3 + 3 dose escalation study design involving 12 patients.
Patients were repeatedly treated intratumorally with ONCOS-102 plus daily low-dose oral cyclophosphamide
(CPO). Tumor response was evaluated with diagnostic positron emission tomography (PET) and computed
tomography (CT). Tumor biopsies were collected at baseline and after treatment initiation for analysis of
immunological correlates. Peripheral blood mononuclear cells (PBMCs) were collected at baseline and during
the study to assess antigen specificity of CD8+ T cells by interferon gamma (IFNγ) enzyme linked immunospot
assay (ELISPOT).
Results: No dose limiting toxicity (DLT) or maximum tolerated dose (MTD) was identified for ONCOS-102. Four out
of ten (40 %) evaluable patients had disease control based on PET/CT scan at 3 months and median overall survival
was 9.3 months. A short-term increase in systemic pro-inflammatory cytokines and a prominent infiltration of TILs
to tumors was seen post-treatment in 11 out of 12 patients. Two patients showed marked infiltration of CD8+ T
cells to tumors and concomitant systemic induction of tumor-specific CD8+ T cells. Interestingly, high expression
levels of genes associated with activated TH1 cells and TH1 type immune profile were observed in the post-
treatment biopsies of these two patients.
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Conclusions: ONCOS-102 is safe and well tolerated at the tested doses. All three examined doses may be used
in further development. There was evidence of antitumor immunity and signals of clinical efficacy. Importantly,
treatment resulted in infiltration of CD8+ T cells to tumors and up-regulation of PD-L1, highlighting the potential
of ONCOS-102 as an immunosensitizing agent for combinatory therapies with checkpoint inhibitors.
Trial registration: NCT01598129. Registered 19/04/2012
Keywords: Immunotherapy, in situ vaccine, Cytotoxic CD8+ T cell, Anti-tumor immunity, Intratumoral, Oncolytic
adenovirusBackground
The concept of oncolytic viruses as cancer therapeutics
has gained considerable attention over the last decade
while expectations regarding the prospect of long lasting
clinical responses with viral therapy are yet to be ful-
filled. The first oncolytic virus entered the market re-
cently when FDA approved T-VEC, a herpes simplex
virus coding for GM-CSF, for the treatment of advanced
melanoma [1]. With the recent excitement around new
immunotherapeutic approaches, especially the concept
of checkpoint molecule blockade, there has been a clear
shift in the way viral cancer therapy is regarded from
providing mainly oncolysis towards being an immuno-
logic form of cancer treatment [2, 3].
The presence of infiltrating immune cells in the tumor
is now recognized as an important prognostic factor as-
sociated with the clinical outcome of many cancer types
[4, 5]. In addition, the localization within the tumor, as
well as the type and functionality of the immune cell in-
filtrates, have a major influence on the host-tumor inter-
actions [4–6]. However, with the recent advances in the
development of checkpoint modulator molecules target-
ing the negative feedback mechanisms that suppress
CD8+ T-cell effector functions, it has become evident
that immune cell-poor cancers are not an optimal target
group for this class of immunotherapy, unless coupled
to an immune priming agent [7, 8].
Immune cell infiltration to tumor is a frequent conse-
quence of treatment with oncolytic viruses, [9] making
them potential immune primers. Adenoviruses are good
immunotherapeutic agents due to their high immuno-
genicity. They can both prime and boost cellular and
humoral immune responses, [10] which is why they
are frequently used as vaccine platforms [11]. Import-
antly, adenoviruses cause cellular immunity with in-
duction of CD8+ T-cells, key effector cells in cancer
immunity [2, 3]. Adenoviruses cause immunogenic cancer
cell lysis where upon tumor antigens previously hidden
from the immune system or not presented in an immuno-
genic context are released into the immunogenic environ-
ment. This results in an induction of T-cell response
against tumor-derived antigens, including unique patient
specific neoantigens. Furthermore, repeated treatmentprovides an update of the antigen repertoire presented to
the immune system. Although the immune response to
virus is strong, a CD8+ T-cell response to tumor antigens is
likely to occur as well [12]. T-cell response may be further
enhanced by immune-stimulating transgenes expressed by
the virus.
ONCOS-102 is a serotype 5 adenovirus that has a gen-
etically modified fiber with a serotype 3 knob for en-
hanced gene delivery to cancer cells [13]. It is armed
with GM-CSF, to enhance antitumor immunity. GM-
CSF recruits antigen presenting cells (APC) and natural
killer (NK) cells. In addition GM-CSF activates and ma-
tures APCs at the tumor site, thereby potentiating the
ability of ONCOS-102 to induce cellular immunity
against the tumor it replicates in [14, 15]. To ensure se-
lective replication in cancer cells and patient safety,
24 bp has been deleted in the Rb binding site of E1A
gene [16].
Up to date, clinical studies of other frequently used
viral platforms, including Herpes simplex virus 1 (HSV1)
and vaccinia virus, have failed to show reliable and con-
vincing results on virus-induced CD8+ T-cell immunity
against cancer, even when the vectors were armed with
GM-CSF [17–20]. This despite these clinical trials being
conducted in melanoma that is known to be one of the
most immunogenic cancer types [21]. In this phase I
study, we assessed safety, efficacy and immunological
endpoints of local treatment with a replicating adeno-
virus ONCOS-102 in 12 patients with late stage solid
cancer of various types including mesothelioma, ovarian
cancer, soft tissue sarcoma, colorectal cancer, liver and
lung cancer. All patients had received chemotherapy and
were treatment refractory, 66 % had had radiotherapy
and 50 % surgery. The median time from diagnosis to
study entry was only 2.5 years.
Results
Safety
Treatments were well tolerated without any grade 4–5
adverse events (AEs) (Table 1). Most AEs were of Grade
1 or Grade 2. Flu-like symptoms and pyrexia were com-
mon AEs, with fever being reported in every patient. A
total of 15 Grade 3 AEs were reported in 6 patients, and
Table 1 Number of patients with related adverse events by
CTCAE grading
Related adverse events CTCAE
grade
Any
grade
MedDRA preferred term 1 2 3
Pyrexia 12 9 2 12
Chills 9 6 10
Fatigue 10 5 1 10
Injection site pain 8 3 9
Decreased appetite 8 1 8
Feeling cold 7 2 8
Hyperhidrosis 5 4 8
Nausea 6 6
Anaemia 3 4 1 5
Pain 3 3 5
Vomiting 5 2 5
Headache 3 3 4
Blood alkaline phosphatase increased 1 2 3
Injection site haematoma 3 3
Night sweats 2 2 3
Abdominal distension 2 1 2
Dyspnoea 1 1 1 2
Pneumonia 2 2
Somnolence 2 2
Upper respiratory tract infection 2 2
Aspartate aminotransferase increased 1 1
C-reactive protein increased 1 1
Dyspepsia 1 1
Hepatic pain 1 1 1
Hypoalbuminaemia 1 1
Hyponatraemia 1 1
Myalgia 1 1 1
Oedema peripheral 1 1 1
Oral herpes 1 1
Proteinuria 1 1
Abdominal pain upper, Arthralgia, Back pain, Cough,
Dizziness, Dyspnoea exertional, Eczema, Haematoma,
Hypovolaemia, Injection site haemorrhage, Iron
deficiency, Libido decreased, Lymphadenopathy,
Malaise, Muscle strain, Muscular weakness, Oedema,
Peripheral coldness, Polyuria, Post procedural
haemorrhage, Pruritus, Urticaria
1 1
No grade 4–5 events were reported
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increased alkaline phosphatase (ALP), increased aspar-
tate aminotransferase (AST), proteinuria, hyponatremia,
anaemia, fatigue, oedema peripheral, and dyspnoea.
There was no indication of a relationship between doseof ONCOS-102 and the incidence and intensity of AEs.
DLT or MTD was not reached in this study.
Systemic pro-inflammatory cytokines
A short-term increase in systemic pro-inflammatory cy-
tokines was seen in all patients following treatment with
ONCOS-102. Concentrations of interleukins 6 and 8
(IL-6 and IL-8) in serum peaked 6 h after intratumoral
ONCOS-102 injections, indicating a rapid innate im-
mune response towards treatment. Cytokines had de-
creased to values close to baseline by 24 h (Fig. 1). The
fever that was seen concomitant with the peak in the
systemic cytokine levels indicates that innate immunity
was evoked by the treatment. Concentration of the anti-
inflammatory cytokine interleukin 10 (IL-10) increased
to some extent post-treatment, but the levels remained
much lower when compared to the pro-inflammatory
cytokines (data not shown). The level of tumor necrosis
factor alpha (TNF-α) remained low or non-detectable in
serum throughout the treatment period in all patients.
The baseline level of systemic GM-CSF was undetectable
or very low in all patients before the first treatment
(range of 0–8 pg/mL). Two patients had post-treatment
increase in systemic GM-CSF level after two injections.
These patients showed an increase in the concentration
of GM-CSF in serum 24 h after the second treatment
(165 and 109 pg/mL). Since the timing of the peak of
GM-CSF concentration is coincidental with the timing
of the gene expression from the E3 replication cassette,
it indicates productive viral replication and transgene
expression in the tumor.
Response according to RECIST 1.1 and PET response
criteria
Of the 12 patients included, two patients passed away
before the first clinical assessment leaving 10 patients
evaluable for radiological response by CT-PET-imaging.
Of these, 4 patients (40 %) had disease control (stable
disease) at 3 months while all patients had progressed at
6 months according to RECIST 1.1 criteria (Table 2).
Four patients had stable metabolic disease based on PET
response at 3 months. Five patients had PET response
data at 6 months, of which 1 patient had stable meta-
bolic disease, and 4 patients had progressive metabolic
disease. Median progression-free survival was 2.9 months
(95 % confidence interval [CI]: 2.7 – 5.5). Median overall
survival was 9.3 months (95 % CI: 3.6 – 12.7) in the per
protocol population (n = 10) and 8.5 months (95 % CI:
3.0 – 12.7) in the intent-to-treat population (n = 12).
Importantly, we saw a late decrease in metabolic activity
in PET imaging of patient FI1-14 with malignant pleural
mesothelioma. In this patient there was a 47 % decrease
in total lesion glycolysis 6 weeks after the last study visit
which occurred at 6 months. The patient had not
Fig. 1 Intratumoral ONCOS-102 treatment triggered a short-term increase in the systemic levels of pro-inflammatory cytokines. Treatment with
ONCOS-102 induced a short-term increase of systemic pro-inflammatory cytokines IL-6 and IL-8 in patients. The increase was most prominent 6 h
after each treatment and decreased nearly to baseline-values by the 24-h time-point
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the decrease in metabolic activity was caused by
ONCOS-102. We believe that the activated immune re-
sponse may lead to the development of delayed yet long-
lived memory response that can sustain clinical benefit
beyond the period of treatment as is often seen with
immune-oncology therapies [22]. This patient survived
18 months (542 days) from the treatment initiation and
over 33 months (999 days) from diagnosis. Patient FI1-19
had an epithelial ovarian carcinoma and had progressive
disease following seven different chemotherapy treatment
lines while entering the trial and continued to progress
during study participation. Interestingly, after the study
she responded to chemotherapy and imaging of her tumor
22 months after the study initiation showed stable disease
compared to baseline and she was alive in the last follow
up 25 months after study initiation.
Virus genomes in blood, urine and buccal swabs, and
neutralizing antibodies in blood
Adenoviruses are rapidly cleared from the bloodstream,
[23] and therefore extended presence or increasing titersin serum suggest viral replication. We analysed the base-
line and post-treatment serum samples for the presence
of ONCOS-102 genomes by quantitative real-time PCR
(qRT-PCR) to evaluate, whether signs of productive rep-
lication were evident after intratumoral treatment. All
patients were negative for ONCOS-102 before the first
treatment and had viral genomes present in the blood-
stream 6 and 24 h post-treatment (Fig. 2). This was
probably indicative of leakage from the injected tumor
instead of productive replication, as the viral life-cycle
lasts for 72 h. At later time-points 9/12 patients showed
a viral titer that was higher than the 24-h titer after pre-
vious treatment, suggesting productive replication and
cell lysis at the injected tumor.
To evaluate the possible virus shedding via urine and
saliva, the presence of ONCOS-102 genomes was ana-
lysed in urine samples from all 12 patients and buccal
swab samples from 9 patients treated in the two highest
dose cohorts. All patients were negative for virus at
baseline, but 4 and 4 patients had a quantifiable level of
viral genomes present in urine and buccal swabs after
treatment, respectively (data not shown). The urine and
Table 2 Patient characteristics, prior treatments, response at 3 and 6 months and overall survival
Patient WHO
score
Cancer type Previous
treatments
(other than
chemotherapy)
Previous chemotherapy Response at
3/6 months
Survival
(days)
RECIST
1.1
PET
FI1-01 1 Ovarian
carcinoma
Surgery,
radiotherapy
Docetaxel + carboplatin, carboplatin, paclitaxel + carboplatin,
paclitaxel, gemcitabine, PLD, etoposide, cisplatin, vinorelbine,
topotecan, oxaliplatin, docetaxel, epirubicin, irinotecan, gemcitabine
hydrochloride, tamoxifen
SD/PD PMD/
SMD
278
FI1-02 0 Metastatic colon
carcinoma
Surgery oxaliplatin, capecitabine, cetuximab + irinotecan + capecitabine SD/PD SMD/
PMD
382
FI1-04 0 Adenocarcinoma
in sigma
- Oxaliplatin + capecitabine + bevacizumab, Capecitabine +
bevacizumab, FolFiri + bevacizumab, xelox
PD/n/a PMD/
n/a
124
FI1-06 0 Hepatocellular
carcinoma
- sorafenib tosilate, ramucirumab PD/n/a PMD/
n/a
109
FI1-08 1 Pulmonum
adenocarcinoma
Radiotherapy pemetrexed disodium + cisplatin, erlotinib hydrochloride, docetaxel PD/n/a PMD/
n/a
155
FI1-09 1 Lung
mesothelioma
- pemetrexed + cisplatin, tramadol hydrochloride PD/n/a SMD/
n/a
254
FI1-13 0 Rectal
adenocarcinoma
Surgery Oxaliplatin + capecitabine, bevacizumab, irinotecan + capecitabine,
panitumumab
PD/n/a PMD/
n/a
290
FI1-14 1 Asbestos related
pleural
mesothelioma
Radiotherapy Docetaxel, cisplatin + pemetrexed disodium SD/PD PMD/
PMD
542
FI1-15 1 Serous
endometrial
cancer
Surgery,
Radiotherapy
PLD, paclitaxel + carboplatin x 2, gemcitabine, topotecan, docetaxel - a - a 90
FI1-17 1 Soft tissue
sarcoma
Surgery,
Radiotherapy
Ifosfamide + doxorubicin, gemcitabine + docetaxel, letrozole,
trabectedin, zoledronic acid, gemcitabine + docetaxel, pazopanib
hydrochloride
PD/PD PMD/
PMD
330
FI1-18 1 Breast cancer Surgery,
Radiotherapy
Docetaxel x2, cyclophosphamide + epirubicin + fluorouracil x 2,
tamoxifen citrate, letrozole, anastrozole x2, exemestane,
bevacizumab, capecitabine, medroxyprogesterone acetate,
vinorelbine tartrate, epirubicin, cisplatin + gemcitabine,
cyclophosphamide +methotrexate sodium
- a - a 63
FI1-19 0 Ovarian cancer Surgery Paclitaxel + carboplatin x 2, paclitaxel + cisplatin, docetaxel + cisplatin,
topotecan, gemcitabine, etoposide
SD/PD SMD/
PMD
761b
PLD Pegylated liposomal doxorubicin hydrochloride, FolFri fluorouracil w/folinic acid/irinotecan, SD stable disease, PD progressive disease, SMD stable metabolic
disease, PMD progressive metabolic disease
aPatient died before the imaging at 3 month time-point
bPatient alive on 16June2015, n/a = patient withdrawn from the trial
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on A549 cells to verify, whether infective particles were
present. A total of 3 patients were positive for infective
virus 3 days after the first ONCOS-102 administration.
One patient had infective viral particles present both in
urine and buccal swab, while 2 patients showed infective
virus only in buccal swabs. Importantly, positive samples
were only collected after the first injection when 20 % of
the dose was given intravenously. All subsequent sam-
ples were negative when the entire dose of ONCOS-102
was given intratumorally. This suggests that systemic ad-
ministration leads to a more widespread biodistribution
of virus compared to intratumoral administration.
8/12 patients were positive for neutralizing antibodies
(NAb) at the baseline, with the NAb titer varying from
<8 to 1024. Titers increased by day 29 in all evaluatedpatients. No correlation was seen between NAb titers
and cytokine levels, immune cell infiltration or overall
survival. Of note, patient FI1-19 had the highest baseline
NAb titer among all patients but nevertheless showed
the biggest post-treatment infiltration of CD8+ T cells
in tumors and concomitant systemic induction of sev-
eral tumor-specific CD8+ T cell populations, indicating
that the presence of pre-existing NAbs did not affect
the biological activity of the intratumoral injections of
ONCOS-102.
Treatment with ONCOS-102 resulted in prominent im-
mune cell infiltration to tumors
Since the presence of TILs has been recognized as a
marker of anti-tumor immune response across a wide
range of tumors [5, 24–27] and a positive correlation
020000
40000
60000
80000
100000
120000
140000)L
m/
P
V(
doolb
ni
selcitraplari
V
Administration day
1 4 8 15 29 57
*
Fig. 2 ONCOS-102 viral particles in blood. ONCOS-102 particles in blood were analyzed before each administration and 6 and 24 h after each
administration. The number of viral genomes peaked at 6-h and lower values were detected 24-h after administration. A secondary peak in
virus titer (*) suggests a productive virus replication at tumor site. Data is presented as median of all patients per time point
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samples and good prognosis, [28] we set out to deter-
mine whether treatment with ONCOS-102 induces im-
mune cell infiltration to tumors. Immunohistochemical
staining revealed that tumor samples taken at baseline
before treatment had variable numbers of CD3+ cells,
CD8+ cells, CD4+ cells, CD68+ cells, CD163+ cells, and
CD11c + cells (Fig. 3). Generally very low numbers of
CD19+ B cells were detected in tumors before and after
ONCOS-102 treatment (Fig. 3). Following treatment
with ONCOS-102, T cell marker CD3 showed aneulav
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Fig. 3 Intratumoral ONCOS-102 treatment induced an infiltration of immun
markers by immunohistochemistry in sequential tumor biopsies was quant
treated in the study are presented. Each solid line indicates an individual pincreased expression levels in post-treatment biopsies
with the median fold-change from baseline being 5.9 in
comparison to same tumors prior to treatment.
ONCOS-102 treatment primarily attracted CD8+ T-cells
in tumors with the median fold-change of 4.0 from
baseline while the median fold-change for CD4+ T-cells
was 2.5. Altogether, 11/12 patients showed a post-
treatment increase in tumor infiltrating CD8+ cells
compared to baseline (Figs. 4 and 5). The highest
fold-increase was observed in the samples of patients
FI1-14 and FI1-19 (131 fold and 1451 fold increase)Baseline After
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Fig. 4 Increased number of immune cells were detected by immunohistochemistry in tumors after ONCOS-102 treatment. A waterfall plot of
indicated CD markers for all patients treated in the trial. Results are presented as the biggest logarithmic fold-change from baseline either 1 month
or 2 months after treatment. Patient code is depicted in each column
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showed a clear infiltration of CD8+ cells in a non-
injected tumor (Fig. 5), which is a possible indication
of a systemic tumor-specific immunity evoked by the
treatment, as the virus was given locally. Further, pa-
tients FI1-14 and FI1-19 also showed a clear increase inthe number of CD68+ and CD11c + cells after treat-
ment, suggesting infiltration of other immune cells,
most likely macrophages and dendritic cells (Fig. 6a
and b). TIL increase post-treatment was associated with
prolonged survival. A statistically significant positive
correlation between survival and infiltration of CD3+,
non-injected
distant lesion
Fig. 5 ONCOS-102 attracted CD8+ lymphocytes to tumors. A prominent infiltration of CD8+ T-cells was seen after treatment (lower row)
in tumors showing very little CD8+ T-cells before treatment (upper row). Of note, patient FI1-15 showed infiltration of CD8+ immune cells
to a non-injected distant tumor
Fig. 6 ONCOS-102 attracted macrophages and B cells to tumors. Infiltration of CD68+ (a), CD11c + (b) and CD19+ (c) immune cells in patients
FI1-14 and FI1-19 was seen after treatment with ONCOS-102
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(Fig. 7). Similarly, absolute numbers of macrophages
(CD68+, CD163+) and T cells (CD3+, CD8+, CD4+) in
post-treatment tumors positively correlated with OS
(data not shown). Interestingly, the absolute expression
level of CD68 (macrophage marker) at baseline nega-
tively correlated with overall survival (p = 0.04, correl-
ation coefficient (r) = −0.59) while baseline levels of
other immune cell markers showed no correlation with
OS. We suggest that tumor associated macrophages
(CD68+ TAMs) present in baseline biopsies were
tumorigenic and supported disease progression as has
been suggested in the literature [29–31]. On the other
hand, positive correlation between post-treatment TILs
and OS suggest that ONCOS-102 was able to modulate
local immunological microenvironment at tumors and
recruit activated immune cells that had cytotoxic prop-
erties and were capable of slowing down the disease1,E-01
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Fig. 7 Increase in tumor-infiltrating immune cells following ONCOS-102 treatm
(CD3+), CD8+ cells, CD68+ cells, CD163+ cells, and CD11c + cells correlated with
the post-treatment increase in different sub-populations of TILs and overall surv
depicted as months, open label is patient FI1-19 who is still aliveprogression. Patient FI1-19 also showed a remarkable
increase in the number of CD19+ cells, suggesting a
prominent infiltration of B-cells to tumors (Fig. 6c).
Tumor infiltrating B-cells have been suggested to enhance
T-cell responses by serving as antigen presenting cells
(APCs), and the co-localization of B-cells with CD8+ TILs
has been shown to be associated with markedly increased
survival compared with CD8+ TILs alone [32–34]. These
results clearly demonstrate the capacity of intratumoral
treatment with ONCOS-102 to evoke cellular immune
responses in tumors that do not have immune cell infiltra-
tion before treatment.
Tumor-specific cellular immune response
Due to the general relative paucity of tumor antigen-
specific T-cells as opposed to the antiviral T-cells,
[35] we wanted to determine whether treatment with
ONCOS-102 is able to induce tumor-specific CD8+1,E-01
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ent is associated with increased survival. The fold change of total T cells
overall survival in patients treated with ONCOS-102. Correlation between
ival was assessed by Spearman’s rank correlation analysis. Overall survival is
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pre- and post-treatment PBMCs to determine specifi-
city of CD8+ T-cells for cancer-testis (CT) antigens
NY-ESO-1, MAGE-A1, and MAGE-A3. The differenti-
ation antigen mesothelin was also analysed for patient
FI1-19 diagnosed with ovarian cancer. Three patients
showed either no IFN-gamma response (FI1-15) or
only modest IFN-gamma response (FI1-02, FI1-08) to
positive control and therefore could not be reliably
assessed for tumor specific CD8+ T cell responses.
Thus, 9 out of 12 patients were evaluable for tumor
specific antigen responses, as their baseline and after
treatment CD8+ T cells showed a clear IFN-gamma
response upon stimulation with a CEF control peptide
pool. All baseline samples were negative for tumor
antigen specific CD8+ T-cells. Two patients had a
clear induction of tumor recognizing CD8+ T cells as
a result of the treatment. Pleural mesothelioma pa-
tient FI1-14 showed a prominent post-treatment in-
duction of MAGE-A3-specific CD8+ T-cells in the
early pool of CD8+ cells collected 8–85 days after
treatment initiation, and MAGE-A3-recognizing CD8+
T cells were still present in the late pool of CD8+ T
cells collected between days 113 and 169 (Fig. 8a).a
b
Fig. 8 Intratumoral ONCOS-102 treatment induced systemic tumor-specific
Systemic, tumor-specific CD8+ cellular response depicted in IFNγ ELISPOT.
and anti-mesothelin ELISPOT for CD8+ T cells for patient FI1 19 (upper row
ESO-1 (p157-165) ELISPOT for patient FI1-19. BL = baseline, pool1 = days 8–
initiation. * = numerical values for anti-NY-ESO-1 (p91-110) ELISPOT at followOvarian cancer patient FI1-19 showed CD8+ T-cell
responses against all three CT antigens (Fig. 8b) as
well as mesothelin (Fig. 8a) in the early post-
treatment pool of CD8+ cells and against MAGE-A1
in the late pool (Fig. 8b). Importantly, CD8+ T-cells
specific for NY-ESO-1 were still present during follow
up period in the blood sample collected 17 months
after the last virus injection. These results suggest that
intratumoral treatment with ONCOS-102 elicits a long-
term, systemic de novo tumor specific immunity despite
the presence of highly immunogenic viral antigens.
TH1-type gene expression profile
Previously, the presence of a broad gene-signature of in-
flammation at the tumor was shown to be predictive for
good prognosis in colon cancer patients [6, 36]. More
specifically, this TH1-type gene-signature indicates in-
nate immune activation, T-cell recruitment and expres-
sion of effector molecules as well as expression of
immune regulatory factors in the tumor. We hypothe-
sized that treatment with ONCOS-102 can induce a
beneficial inflammatory environment within the tumor
by inducing the expression of genes related to TH1-type
gene signature. Gene expression profiling by microarraynegative control 
(no peptide)
tumor specific
peptide
CD8+ T cell responses in chemotherapy refractory cancer patients.
a Anti-MAGE-A3 ELISPOT for CD8+ cells in patients FI1-14 (lower row)
). b Numerical values for anti-MAGE-A3, anti-MAGE-A1 and anti-NY-
85 after treatment initiation, pool 2 = days 113–169 after treatment
-up 17 months after the last ONCOS-102
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related to TH1-type signature, specifically markedly ele-
vated expression levels of genes encoding cytotoxic fac-
tors perforin, granzyme B and granulysin post-treatment
(Table 3), suggesting that the treatment-induced TILs
displayed effector functionality. Further, elevated expres-
sion levels of genes encoding TH1 associated factors
such as interferon gamma (IFNγ) and interferon regula-
tory factor 1 (IRF1), and TH1 associated chemokines
(CCL2, RANTES, CX3CL1, CXCL9 and CXCL10) were
seen post-treatment as well.
Treatment with ONCOS-102 induces PD-L1 expression in
the tumor
Therapies targeting the programmed death 1 (PD-1) re-
ceptor have shown great promise in cancer treatment,
resulting in durable responses in various cancer types
[37–42]. Recently it has been suggested that the pres-
ence of PD-1 expressing CD8+ T-cells at the invasive
tumor margin and inside the programmed death 1 lig-
and (PD-L1) expressing tumor is a prerequisite for suc-
cessful anti-PD-1 therapy [7]. Furthermore, an increased
PD-L1 expression in tumor cells has been suggested to
reflect the presence of active anti-tumor immune re-
sponse [43]. Therefore, we wanted to analyse whether
the treatment with ONCOS-102 has an impact on the
PD-L1 expression status of the treated tumors. Indeed,
we saw a clear post-treatment induction of PD-L1 ex-
pression in the tumors of two mesothelioma patients,
with PD-L1 histoscore increasing from baseline levels of
17 and 1 to 47 and 23 after treatment, respectively
(Fig. 9a). As both patients also showed a prominent infil-
tration of CD8+ T-cells to the tumor (Figs. 4 and 5) after
treatment and a clear increase in the gene expression
level of IFNγ in tumor (Fig. 9b), these findings suggest
induction of dynamic adaptive changes in response to T-
cell-derived IFNγ [44].Table 3 Expression of genes related to a TH1 type gene
signature before and after treatment in selected patients
FI1-09 FI1-14 FI1-19
Gene baseline after baseline aftera baseline after
Granzyme B 7.3 8.5 7.2 10.1 na 9.9
Granulysin 8.3 7.2 7.1 9.0 na 8.9
Perforin 7.3 8.1 7.1 9.6 na 9.7
IFNγ 6.8 7.7 6.9 8.6 na 7.6
IRF1 9.3 10.7 10.6 11.9 na 11.9
RANTES 8.4 11.6 9.3 12.9 na 12.3
CXCL9 7.5 10.8 9.3 12.4 na 10.5
CXCL10 8.7 10.5 10.2 11.8 na 10.3
Baseline = before treatment, after = 2 months after the treatment initiation
a= 1 month after the treatment initiation
IFNγ interferon gamma, IRF1 interferon regulatory factor 1Discussion
The primary endpoint of this study was to identify a safe
and tolerated dose for phase II investigation. Since repli-
cation is essential to the mechanism of action of oncoly-
tic adenoviruses, they typically have a non-linear toxicity
curve. Consequently, no correlation was expected be-
tween dose and toxicity on the contrary to what would
be expected in a study with a pharmacological agent.
Therefore, no further dose escalation was performed
even though no DLTs were observed in any dose cohort.
This is in line with studies with other oncolytic viruses,
where the MTD has not been reached [45–47]. It can be
argued that MTD is not relevant based on the mechan-
ism of action of oncolytic viruses where viral replication
triggers the initiation of both direct cancer cell death
and activation of the innate and adaptive immune
system. The highest dose, 3 × 1011 VP/injection, was
chosen as the recommended dose for further develop-
ment, although any of the three doses examined in this
study could potentially be used.
Cancer immunotherapeutic agents have been devel-
oped mainly as systemically administered drugs. How-
ever, most approaches, and especially the successful
PD-1/PD-L1 blocking agents, are hampered by the
commonly hypo-reactive local immune system in the
tumor. Our strategy, in contrast, is to tackle the im-
mune exhausted tumor microenvironment with locally
delivered ONCOS-102 to prime anti-tumor immunity.
By local administration, we maximise the safety of the
treatment and circumvent the possibility of NAbs
hampering efficacy. Indeed, some controversy is re-
lated to the significance of NAbs with regard to the
efficacy of viral immunotherapy of cancer. While they
clearly present a hurdle to systemic injections, leading
to significantly reduced transfection of target cells,
[48] the relevance of NAbs in a local setting is less
clear. Importantly, we show that the efficacy of local
treatment with ONCOS-102 is not hampered by the
presence of pre-existing NAbs in the blood. Further, due
to the marked liver-tropism of viruses, systemic adminis-
tration requires very high doses of virus to saturate liver
Kupffer cells and hepatocytes in order to achieve sufficient
levels at the target tissues [49, 50]. Accumulation in the
liver is accompanied by an acute phase immune response
with elevated levels of cytokines such as IL-6 and TNF-α
that can lead to life threatening systemic immunity [51].
We saw no indication of virus-related toxicity due to the
elevated levels of IL-6 and IL-8, a safety aspect further
strengthening the rationale behind our choice of local
treatment instead of systemic.
The presence of tumor infiltrating lymphocytes (TILs),
especially CD8+ T-cells, has been recognized as a
marker of anti-tumor immune response across a wide
range of cancers, [5, 24–27] and a positive correlation
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Fig. 9 ONCOS-102 treatment induced up-regulation of PD-L1 in tumors. The increase in PD-L1 expression (a) coincided with an infiltration of
CD8+ cells (Fig. 6) and an increase in gene expression of IFN-γ in tumors in mesothelioma patients FI1-14 and FI1-09 (b), suggesting induction of
dynamic adaptive changes in response to T-cell-derived IFNγ
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samples and good prognosis [28, 52, 53]. Further,
pre-existing CD8+ T-cells seem to be required to
achieve clinical efficacy with PD-(L)1 checkpoint
blockade [7, 8, 54]. In established and progressing
cancer, however, TILs often show an exhausted func-
tional state similar to what is seen in chronic viral
infection [55–58] due to persistent tumor-antigen
load, adaptive responses in cancer cells and im-
munosuppressive factors in the tumor microenviron-
ment. This is highlighted in last-line cancer patients
where the immunosuppressive state of the tumor is often
extensive, with exhausted (unfunctional) lymphocyte
phenotype, high level of regulatory T cells or no indication
of pre-treatment TILs [28, 52, 53, 59–62]. Thus, new com-
plementary strategies are required to activate cellular
antitumor immunity in immune cell-poor cancers.
This study demonstrates that ONCOS-102 is able to in-
duce cellular antitumor immunity. We believe that thisimmune priming ability is a consequence of the innate im-
mune system activation via pattern recognition receptors
(PRRs) (e.g. toll-like receptors 2 and 9) and immunogenic
cancer cell death that ONCOS-102 causes. Immunogenic
cancer cell death is associated with the presentation of cal-
reticulin on the cell surface and the release of natural
adjuvants, specifically high-mobility group protein B1
(HMGB1) and ATP from within the dying cells, [9, 63]
eventually leading to DC stimulation and subsequent acti-
vation of adaptive immune response [64]. We think that
this “danger environment” created by ONCOS-102 [65]
was essential in breaking the tolerance against tumor anti-
gens that are essentially “self” and, by definition, either
weakly immunogenic or functionally non-immunogenic
due to the immunologically compromised tumor environ-
ment. Some encouraging previous data from local T-VEC
treatment exist suggesting stimulation of both local and
systemic tumor antigen-specific T cell immunity [20].
Unfortunately the small sample size and the absence of
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cance of these findings.
It is important to bear in mind that the small size (12
patients) and heterogeneity of the patient population in
this phase I trial makes any definite conclusions regard-
ing clinical benefit impossible. Yet, it is noteworthy that
we show infiltration of CD8+ T-cells to tumors that
were negative at baseline, and induction of systemic
tumor antigen-specific T-cell response resulting from
viral treatment. Importantly, the patients had late stage
refractory diseases of varying origin with no further
treatment options left to consider. A virus-induced cellu-
lar immune response in such a patient population is an
encouraging proof of the ability of ONCOS-102 to
awaken anti-tumor immunity in highly immune sup-
pressed tumors. Further, this effect was seen in cancer
types that differ from melanoma that is known to be
highly immunogenic with high mutation rates that lead
to frequent spontaneous immune cell infiltration to
tumors and tumor-specific T cell responses [21, 66]. In
case of viral immunotherapy, tumor antigens that are es-
sentially “self” must compete against highly immuno-
genic viral antigens that are foreign, and this may limit
the immune response to tumor, highlighting the import-
ance of our findings [12]. Indeed, the choice of vector
is critical as viruses differ in ways that affect their
immunogenicity and oncolytic potential. Generally a
highly immunogenic virus has a somewhat restricted
oncolytic potential due to the brisk host immune
responses, and vice versa [67]. Due to its immuno-
genic nature, ONCOS-102 is well suited for immuno-
therapy approaches.
Importantly, the two patients with the most prominent
treatment-induced infiltration of CD8+ T-cells to tumor
as well as a systemic anti-tumor cellular response had
the best overall survival. Previously, some indication of
favourable anti-tumor immunity was presented in a mul-
ticentre phase II study where metastatic melanoma pa-
tients were treated with T-VEC, an oncolytic herpes
simplex virus coding for GM-CSF [20].
Treatment with ONCOS-102 also induced a TH1 type
gene signature, and the presence of markers for TH1
polarization in the tumor has been implicated as im-
portant factor in predicting clinical outcome of patients
[6, 36]. Interestingly, inflammatory cytokines, especially
IFNγ, also cause dynamic adaptive changes of cancer
cells [44, 68]. The immune inhibitory ligand PD-L1 on
cancer cells is upregulated in response to T-cell-derived
IFNγ, and engages PD-1 on T-cells, thereby attenuating
their effector functions. We have shown that treatment
with ONCOS-102 not only induces T-cell effector
functions but also upregulates PD-L1 expression on tu-
mors. This phenomenon is likely due to the CD8+ T-cells
infiltrating the tumor as a response to the immunogeniccancer cell death caused by ONCOS-102. As biopsies
represent a snapshot of the tumor immune microenviron-
ment with temporal and dimensional restrictions, small
samples may miss the relevant sites for PD-L1 ex-
pression and the time-point may be less than opti-
mal for biologically relevant PD-L1 expression to
occur [69]. To this end, it is noteworthy that this
adaptive response could be seen in some patients
after treatment, further highlighting the potential of
ONCOS-102 to prime immune cell-poor tumors for
PD-1/PD-L1 blockade.
Conclusions
We show that locally administered ONCOS-102 is well
tolerated and results in the induction of local and sys-
temic CD8+ T-cell immunity against tumor in patients
with treatment refractory and immune cell-poor cancers.
Further, a dynamic adaptive change in cancer cells
depicted in the form of PD-L1 up-regulation after treat-
ment was seen, and together these results award further
investigations into the combination of ONCOS-102 with
other immune therapies such as PD-1/PD-L1 inhibitors.
Methods
Patient characteristics, inclusion and exclusion criteria
Twelve patients with solid tumors refractory to avail-
able treatments were treated in this phase I clinical trial
with ONCOS-102 (Table 1). Inclusion criteria included
age over 18 years, a solid refractory tumor confirmed by
histology and at least one tumor measurable by PET
plus suitable for biopsy and WHO performance score of
0–1. Exclusion criteria included the use of high dose im-
mune suppressive medication, vaccination with a live
virus within 4 weeks of treatment, severe or unstable
cardiac disease, known brain metastases, glioma, or cen-
tral nervous system malignancy, HIV, history of hepatic
dysfunction, cirrhosis or hepatitis, organ transplant or a
clinically active infection or medical condition that, in
the opinion of the principal investigator, might interfere
with the investigation. The study was approved by the
Hospital District of Helsinki and Uusimaa Ethics Com-
mittee, Department of Surgery. Written informed con-
sent was obtained from patients prior to treatment, and
the study was conducted in compliance with Good Clin-
ical Practice guidelines.
ONCOS-102
ONCOS-102 (previously called CGTG-102 and Ad5/3-
D24-GMCSF) is a serotype 5 adenovirus that features a
chimeric capsid with a serotybe 3 fiber knob for en-
hanced gene delivery to cancer cells and a 24 bp dele-
tion in Rb binding site of E1A for cancer cell restricted
replication. ONCOS-102 is armed with granulocyte-
macrophage colony-stimulating factor (GM-CSF), a
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tion of ONCOS-102 has been described elsewhere [13].
Manufacturing of ONCOS-102 for the trial was car-
ried out in accordance with Good Manufacturing
Practice (GMP).
Study design and treatments with ONCOS-102 and
cyclophosphamide
This was an exploratory, uncontrolled, non-randomised,
un-blinded study of intratumoral (i.t.) and intravenous
(i.v.) ONCOS-102, in conjunction with low dose cyclo-
phosphamide (CPO), in patients with solid tumors that
were refractory to available treatments (NCT01598129).
The primary objective of the study was to determine the
optimal dose of ONCOS-102 for use in Phase II and
further development. As secondary objectives, the safety
and tolerability of ONCOS-102 with low dose CPO were
studied. Further, we sought to obtain preliminary evi-
dence of disease control by ONCOS-102, as well as to
determine the response rate to ONCOS-102 and the
overall survival of patients treated in the trial. As ex-
ploratory endpoints, the effect of ONCOS-102 on im-
munological and biological correlates, especially cellular
immune responses, were determined.
This was a classic 3 + 3 dose escalation study. The
total i.t. doses of ONCOS-102 were 3 × 1010 virus parti-
cles (VP)/injection (low dose), 1 × 1011 VP/injection
(mid dose), and 3 × 1011 VP/injection (high dose) on
days 1, 4, 8, 15, 29, 57, 85, 113 and 141. I.t. injection
encompassed intrapleural and intraperitoneal (i.p.) injec-
tion where appropriate. On Day 1 only, 20 % of the dose
was administered intravenously (i.v.) and on subsequent
days, 100 % was given i.t. I.t. injections were given by
ultrasound guided needle. CPO 50 mg/day p.o. CPO
(Baxter, Halle, Germany) was given daily until day 141,
starting on day 2. PBMCs were collected before each
ONCOS-102 administration and diagnostic positron
emission tomography (PET) and computed tomography
(CT) scans were performed on days 85 and 169.
Tumor biopsies and blood samples
A core needle biopsy of the tumor was taken at baseline
before the first treatment and one (day 29) and 2
months (day 57) after the treatment initiation. The
sample was transferred immediately on a pre-cooled
petri dish to sterile 0.9 % NaCl solution and divided
into pieces for further analysis. For RNA-extraction, a
part of the sample was immediately snap frozen on dry
ice and stored in −80 °C. For immunohistochemistry
(IHC) analysis, a part of the sample was placed in 10 %
formalin buffer and kept at room temperature. Blood
samples were collected from serum (3.5 ml in serum
gel tube) and whole blood (2 ml in EDTA tube) before
each treatment and 6 and 24 h after each treatment.Serum samples were centrifuged and frozen to -20 °C
and whole blood samples were frozen to −20 °C after
collection. Blood samples for leucocytes (32 ml before
treatment initiation and 16 ml before each subsequent
treatment in CPT tubes) were immediately processed
for leucocyte isolation.Leucocyte isolation and IFNγ ELISPOT
The PBMCs were isolated using vacutainer cell prepar-
ation (Beckton Dickinson, Franklin Lakes, NJ, USA), and
suspended into 1 ml CTL-CryoTMC-reagent (Cellular
Technology Limited, Shaker Heights, OH, USA). The
cell concentration was counted in a haemocytometer-
chamber (C-Chip disposable Haemocytometer, Digital
Bio) under a 40 x objective. The live cells were separated
from the dead cells by using Trypan blue solution
(Amresco, Solon, OH, USA). CTL-CryoTMA and CTL-
CryoTMB were combined and added to the cell solution
according to the manufacturer’s instructions, and the
cell solution was frozen on isopropanol container at
−80 °C and further transferred to −140 °C.
Standard gamma IFN-ELISPOT was performed from
pre- and post-treatment samples to analyse, whether
the treatment induced tumor-specific cytotoxic T cell-
responses. CD8+ T-cells purified with MACS® cell
separation column (Miltenyi Biotech, Lund, Sweden)
were pre-sensitized with peptide-pulsed, irradiated
autologous PBMCs depleted of CD4+ and CD8+ T-
cells. Pre-sensitized CD8+ T-cells were tested on day 10–
12 by IFNγ ELISPOT assay for recognition of peptide-
pulsed T2 cells or peptide-pulsed autologous antigen-
presenting cells (EBV-transformed B cells or DCs). The
number of cytokine-producing antigen-specific T-cells
was evaluated using AID EliSpot Reader Classic ELR 07
(Autoimmun Diagnostika GmbH, Strassberg, Germany).
Based on the patient’s HLA haplotype, we analyzed
CD8+ T-cell responses against NY-ESO-1, MAGE-A1,
MAGE-A3 (MAGE-A1: (HLA-A1)EADPTGHSYp161-
169 (HLA-A2)KVLEYVIKVp278-286, (HLA-B35)EAD
PTGHSYp161-169; MAGE-A3: (HLA-A1)EVDPIGH-
LYp168-176, (HLA-A2)FLWGPRALVp271-279, (HLA-
A2)KVAELVHFL p112-120, (HLA-A35)EVDPIGHLYp
168-176, (HLA-B18)MEVDPIGHLYp167-176 (HLA-B
44)MEVDPIGHLYp167-176; NY-ESO-1: (HLA-A2)SL
LMWITQCp157-165, (HLA-B35)MPFATPMEA p94-
102, (HLA-B51)MPFATPMEAp94-102, (HLA-Cw3)LA
MPFATPM p92-100) and/or known CD8 antigenic
epitopes shown in the peptide database from van der
Bruggen on http://www.cancerimmunity.org/peptide/.
CD8+ T cell response against mesothelin for patient
FI1-19 was analysed using overlapping long peptides
kindly provided by Professor Markus Maeurer from
Karolinska Institutet, Sweden.
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For analysis of different leucocyte populations on bi-
opsy samples, three μm sections were cut from
formalin-fixed and paraffin-embedded (FFPE) tissues
and processed for immunohistochemistry performed
with Ventana BenchMark XT immunostainer (Ventana
Medical Systems, Tucson, AZ, USA). Rabbit monoclo-
nal antibodies used were as follow: anti-CD8 clone
SP57 (ready to use, Ventana), anti-CD4 clone SP35
(Cell Marque, Rocklin, CA, USA). Mouse monoclonal
antibody for CD68 was clone KP1 (Dako, Glaustrup,
Denmark), for CD11c clone 5D11 (Novocastra, Leica
Microsystems GmbH, Wetzlar, Germany) and for CD19
clone LE-CD19 (Dako). Visualization was done using
either UltraView Dabv3 (for CD8 and CD68), OptiView
DAB IHCv3 (for CD4) or Envision K5007 (Dako) (for
CD11c and CD19) with amplification (Ventana). The
specimens were counterstained with hematoxylin and post
counterstained with bluing reagent.
For quantitation, a color information based image pro-
cessing methodology was applied. Samples were digitally
scanned (3DHISTECH Ltd, Panoramic 250 FLASH,
Budapest, Hungary and VCC-F52U25CL camera, CIS,
Tokyo, Japan) and the images were compressed to a
wavelet file format (Enhanced Compressed Wavelet,
ECW, ER Mapper, Erdas Inc, Atlanta, Georgia) and ar-
chived online using Webmicroscope whole-slide image
management platform (WebMicroscope, Fimmic Ltd,
Helsinki, Finland) running with image server software
(Erdas Apollo Image Web Server, Intergraph, Norcross,
GA). Uneven background illumination was corrected,
exclusively positively stained cellular regions were identi-
fied and possible unspecific staining was filtered out.
Finally, the immunohistochemically stained samples
were quantified by calculating a fraction of positively
stained cellular region in the total tissue area. The
image-processing pipeline was implemented in matrix
laboratory (MATLAB, version R2012b) numerical com-
puting environment.
For the analysis of PD-L1 molecule on tumor biopsy
samples, four μm sections were cut from FFPE tissues,
mounted on glass microscope slides and processed for
immunohistochemistry using EnVisionTMFLEX Target Re-
trieval System (Dako). Rabbit primary monoclonal PD-L1
XP® antibody (1:500) (clone EIL3N, Cell Signaling, Danvers,
MA, USA) and FLEX+Rabbit (clone SM805, Dako) anti-
body as a secondary antibody were used and visualization
was achieved by using a labelled polymer (FLEX/HRP) and
DAB+ Substrate-Chromogen (Dako).
Microarray analysis
Total RNA was extracted from snap-frozen core needle
tumor biopsies taken at baseline and 1 and 2 months
after the treatment initiation and gene expressionprofiling was performed by using HumanHT-12 Illumina
microbead chips according to the standard protocols
(Illumina Inc, San Diego, CA, USA). The probe-group
intensity data were called using BeadStudio without
background correction and normalization. The non-
processed average signal values were then quantile-
normalized, log2-transformed, and annotated using the
package lumi (Bioconductor open source software).
Chip-dependent batch-effects were removed using em-
pirical Bayes methods [70]. Probes assigned to same
Entrez gene identifier were averaged into a single ex-
pression estimate and probes left without gene informa-
tion were removed. Differential expression analysis of
the normalized data was performed using the Limma-
package [71] by employing a paired t-test (pairing was
done over samples originating from the same patient).
The Storey’s Q-value adjustment [72] was used to cor-
rect data for multiple hypothesis testing.PET and CT scan
Changes in tumor metabolism and size was evaluated
using fluorodeoxy-D-glucose (FDG) PET and diagnostic
CT imaging at the screening visit, on Day 85 and at end
of treatment (Day 169). The metabolic activity in PET
was measured as maximum standardized uptake values
(SUV max) from two measurement points in the tumor,
or as total lesion glycolysis for patient FI1-14 for max-
imal reliability of the results. The response was evaluated
using Response Evaluation Criteria in Solid Tumours
version 1.1 (RECIST1.1) and PET response criteria.Adverse events
Physical assessment of the patients was done at every
visit. Laboratory variables and other safety measures
were analysed, i.e. standard CRP values, haematology
abnormalities, liver enzymes ASAT and ALP, and
blood potassium creatinine, sodium or INR after each
treatment. Also blood pressure, pulse and SaO2 level
were measured. Body temperature was measured and
managed successfully with paracetamol or ibuprofen,
if needed. Side effects were recorded according to
common terminology criteria version 4 for adverse
events (CTCAE ver. 4.0).Cytokines in blood
Cytokines were quantified from serum by using cytomet-
ric bead array system (CBA) (BD, Franklin Lakes, NJ,
USA) for each cytokine. The analysis was performed ac-
cording to the manufacturer’s instructions (BD Human
Soluble Flex Set Kits), and the samples were run on BD
LSRFortessaTM flow cytometric cell analyser and the re-
sults were plotted using BD FACSDiva software.
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DNA isolation for qRT-PCR was done using a Kit for
isolation of DNA from body fluids (Generi Biotech,
Hradec Kralove, Chzech Republic) according to the
manufacturer’s protocol. A specific adenovirus PCR prod-
uct was prepared from the genomic DNA of ONCOS-102
and cloned to a plasmid pCR4 TOPO TA (Invitrogen, Life
Technologies, Thermo Fisher Scientific, Waltham, MA,
USA) to be used as a positive control standard for the qRT-
PCR assay. The qRT-PCR was done using primers
Ad_dE1#1 CTATGCCAAAACCTTGTACCG and Ad_dE
1#2 TCCTCACCCTCTTCATCCTC and probe Ad_E1#P
TGATCGATCCACCCAGTGACGAC targeting the E1
gene, specifically the region with the 24 bp deletion. A trad-
itional lambda phage-target specific internal amplification
control (primers PhgL_Q2#1 AAAAAGGATGAATCGCT
TGGTGTA and PhgL_Q2#2 AATCCTGAATTTTCGGT-
GATG and probe PhgL_Q2#PCCATCGTGCCGCGACT
GC) was used to avoid false-negative results [73].
Titer of the neutralizing antibodies
The determination of neutralizing antibody titer from
patient serum was done as described previously [74].
Briefly, a non-replicating luciferase-expressing Ad5/3lucI
adenovirus was used to analyse the effect of neutralizing
antibodies on the gene transfer efficacy of the virus, and
thereby to evaluate the relative amount of neutralizing
antibodies in patient serum before and after treatment.
Ad5/3lucI was incubated with complement-inactivated
patient serum dilutions (four-fold from 1:1 – 1:16384),
and the mixture was added on A549 cells for luciferase
activity measurement 24 h later. The Nab titer was de-
termined as the lowest degree of dilution that blocked
the luciferase gene transfer more than 50 % compared to
virus alone.
Statistical methods
Descriptive statistics for the safety and efficacy measures
were calculated and displayed by dose group. Categorical
data were presented by number of patients and percent
for each category. Continuous data were presented by
means and standard deviation (SD). Kaplan-Meier esti-
mates were utilised for time-to-event analysis. AEs were
coded using the Medical Dictionary for Regulatory Ac-
tivities (MedDRA, version 15.0), and were summarised
by system organ class (SOC) and preferred term (PT).
Exploratory correlation analysis using Spearman’s
method was applied to absolute values and fold-change
from baseline in TILs vs. overall survival.
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